HHS awards $190.6M for Sanofi Pasteur H1N1 vaccine antigen
Contract Overview
Contract Amount: $190,575,000 ($190.6M)
Contractor: Sanofi Vaccines US Inc.
Awarding Agency: Department of Health and Human Services
Start Date: 2009-05-22
End Date: 2013-05-28
Contract Duration: 1,467 days
Daily Burn Rate: $129.9K/day
Competition Type: COMPETITIVE DELIVERY ORDER
Number of Offers Received: 3
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: SANOFI PASTEUR H1N1 BULK VACCINE ANTIGEN AT 15UGHA DOSE (CAN 1993418)
Place of Performance
Location: SWIFTWATER, MONROE County, PENNSYLVANIA, 18370, UNITED STATES OF AMERICA
Plain-Language Summary
Department of Health and Human Services obligated $190.6 million to SANOFI VACCINES US INC. for work described as: SANOFI PASTEUR H1N1 BULK VACCINE ANTIGEN AT 15UGHA DOSE (CAN 1993418) Key points: 1. The contract awarded to Sanofi Vaccines US Inc. is for H1N1 bulk vaccine antigen. 2. This is a competitive delivery order valued at $190.6 million. 3. The contract duration is 1467 days, ending in May 2013. 4. The North American Industry Classification System (NAICS) code is 325411, indicating Medicinal and Botanical Manufacturing.
Value Assessment
Rating: good
The contract value of $190.6 million for vaccine antigen appears reasonable given the scale and duration. Benchmarking against similar pandemic preparedness contracts would provide a more precise assessment.
Cost Per Unit: N/A
Competition Analysis
Competition Level: unknown
This was a competitive delivery order, suggesting that multiple vendors were considered. The competitive nature likely contributed to price discovery and a more favorable outcome for the government.
Taxpayer Impact: The award represents a significant investment in public health preparedness, aiming to secure a vital medical countermeasure against a potential pandemic.
Public Impact
Ensures availability of critical vaccine components for public health emergencies. Supports national biodefense and pandemic preparedness efforts. Potential impact on vaccine supply chain and pricing for future health crises.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Contract duration extends beyond the typical H1N1 pandemic timeline.
- Lack of specific performance metrics or quality assurance details in the provided data.
Positive Signals
- Awarded competitively, suggesting potential for good value.
- Addresses a critical national security and public health need.
Sector Analysis
The contract falls under the Healthcare sector, specifically related to pharmaceutical manufacturing and public health preparedness. Spending benchmarks for pandemic-related vaccine procurement can vary widely based on the specific threat and market conditions.
Small Business Impact
The data does not indicate any specific provisions or set-asides for small businesses in this contract award.
Oversight & Accountability
Oversight would typically be managed by the Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS, ensuring adherence to contract terms and delivery schedules.
Related Government Programs
- Medicinal and Botanical Manufacturing
- Department of Health and Human Services Contracting
- Office of Assistant Secretary for Preparedness and Response Programs
Risk Flags
- Long contract duration may exceed the immediate threat period.
- Potential for obsolescence if H1N1 strain mutates significantly.
- Dependence on a single supplier for a critical component.
- Limited information on specific quality assurance and performance metrics.
Tags
medicinal-and-botanical-manufacturing, department-of-health-and-human-services, pa, do, 100m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $190.6 million to SANOFI VACCINES US INC.. SANOFI PASTEUR H1N1 BULK VACCINE ANTIGEN AT 15UGHA DOSE (CAN 1993418)
Who is the contractor on this award?
The obligated recipient is SANOFI VACCINES US INC..
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).
What is the total obligated amount?
The obligated amount is $190.6 million.
What is the period of performance?
Start: 2009-05-22. End: 2013-05-28.
What was the specific justification for the large quantity and duration of the H1N1 vaccine antigen procurement?
The large quantity and extended duration were likely driven by a strategic assessment of potential H1N1 pandemic severity and the need to ensure a robust domestic supply chain for vaccine production. This proactive approach aimed to mitigate risks associated with rapid onset and widespread transmission, allowing for timely vaccine manufacturing and distribution.
How did the competitive bidding process ensure the best value for taxpayer dollars in this vaccine antigen contract?
A competitive bidding process allows multiple qualified vendors to submit proposals, including pricing. This fosters price discovery and encourages vendors to offer their most competitive rates to secure the contract. The government can then evaluate not only price but also technical capabilities and past performance to select the best overall value.
What measures were in place to ensure the effectiveness and timely delivery of the vaccine antigen, given the potential for a rapidly evolving pandemic?
Effectiveness and timely delivery would typically be ensured through stringent contract terms, including detailed specifications for the antigen, quality control measures, and defined delivery schedules. The contracting agency, ASPR, would likely monitor production closely and have contingency plans for addressing any delays or quality issues to maintain readiness.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: COMPETITIVE DELIVERY ORDER
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Solicitation ID: RFPHHSBARDA0825
Offers Received: 3
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Parent Company: Sanofi Pasteur Vaxdesign Corp (UEI: 739980787)
Address: DISCOVERY DR, SWIFTWATER, PA, 18370
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business
Financial Breakdown
Contract Ceiling: $190,575,000
Exercised Options: $190,575,000
Current Obligation: $190,575,000
Contract Characteristics
Multi-Year Contract: Yes
Parent Contract
Parent Award PIID: HHSO100200800073I
IDV Type: IDC
Timeline
Start Date: 2009-05-22
Current End Date: 2013-05-28
Potential End Date: 2013-05-28 00:00:00
Last Modified: 2015-08-01
More Contracts from Sanofi Vaccines US Inc.
- 00hcvgbc-2009-68767 - Sanofi VFC Pediatric Vaccine Contract — $737.3M (Department of Health and Human Services)
- Vaccince for Children 2010 — $709.2M (Department of Health and Human Services)
- Vaccine for Children 2011 — $640.0M (Department of Health and Human Services)
- Vacccine for Children 2008 Contract — $590.5M (Department of Health and Human Services)
- VFC 2012 — $589.8M (Department of Health and Human Services)
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →